Positron Emission Tomography for Detecting Clinically Occult Surgically Resectable Metastatic Ovarian Cancer
- 30 April 2002
- journal article
- case report
- Published by Elsevier in Gynecologic Oncology
- Vol. 85 (1), 196-200
- https://doi.org/10.1006/gyno.2002.6611
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Positive Emission Tomography for Evaluating a Complete Clinical Response in Patients with Ovarian or Peritoneal Carcinoma: Correlation with Second-Look LaparotomyGynecologic Oncology, 2001
- Clinical Value of Positron Emission Tomography with FDG for Recurrent Ovarian CancerAmerican Journal of Roentgenology, 2001
- Combined PET/CT Imaging in Oncology Impact on Patient ManagementClinical Positron Imaging, 2000
- Clinical Impact of 18F-FDG-PET in the Suspicion of Recurrent Ovarian Carcinoma Based on Elevated Tumor Marker Serum LevelsClinical Positron Imaging, 2000
- Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose in oncologyZeitschrift für Krebsforschung und Klinische Onkologie, 2000
- Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinomaEuropean Radiology, 2000
- Positron Emission Tomography for Evaluating Para-aortic Nodal Metastasis in Locally Advanced Cervical Cancer Before Surgical Staging: A Surgicopathologic StudyJournal of Clinical Oncology, 1999
- Experience with Positron Emission Tomography (PET) Scans in Patients with Ovarian CancerGynecologic Oncology, 1994
- Whole-Body Positron Emission Tomography with 2-[18F]-Fluoro-2-deoxy-D-glucose Can Detect Recurrent Ovarian CarcinomaGynecologic Oncology, 1993
- Assessment of Primary and Metastatic Ovarian Cancer by Positron Emission Tomography (PET) Using 2-[18F]Deoxyglucose (2-[18F]FDG)Gynecologic Oncology, 1993